Immunic, Inc.· IMUX

🇺🇸 US · MicroBroad USNASDAQ

HealthcareBiotechnologyWebsite

Price: $14.05
Day: -0.35%
Mkt Cap: $191.38M
52W Range: $5.06 – $15.84
Volume: 182.6K
Beta: 1.38

D35D Framework

Valuation Analysis

Intrinsic-value engines paired with peer-anchored multiples.

Blog

stockoscope.com

Immunic, Inc.

IMUX|Healthcare|Biotechnology

Valuation Multiples

Dimension 3 of 5

Current Price

$14

Market Price

Multiples Estimate

$124

Peer-Median Composite

P/E

N/A

Price / Earnings

FCF Yield

N/A

Free Cash Flow Yield

Looking for intrinsic value? See IMUX's intrinsic value on stockoscope.com.

Peer-Implied Values

What the stock would be valued at the sector median for each multiple (162 peers)

Valuation Multiples at a Glance

Current multiple vs. sector median

P/B

0.3x

Sector: 2.5x

P/E: Price-to-Earnings · PEG: P/E-to-Growth · P/B: Price-to-Book · P/S: Price-to-Sales · P/FCF: Price-to-Free-Cash-Flow · FCF: Free Cash Flow · EV: Enterprise Value · EBITDA: Earnings Before Interest, Taxes, Depreciation & Amortization · EBIT: Earnings Before Interest & Taxes

See the complete picture

The full 5D Framework: Business Quality · Peer Comparison · Valuation · Analyst Sentiment · Smart Money

Explore IMUX on stockoscope.com→

Generated August 5, 2026

For educational purposes only. Not financial advice. Data may be delayed or incomplete.

Valuation Assessment

IMUX Valuation Summary

How sector peers and the stock's own history value it (no intrinsic model available for this stock)

Market only · blended estimate

—

2 readings sit beyond +10% and show as arrows past the end of the axis. Hover or tap one for its value.

The estimate reconciles the values implied by sector peers and the stock's own trading history (no intrinsic model available for this stock).Last updated August 5, 2026.

Valuation Multiples

Per-metric breakdown of how IMUX is priced relative to its sector peers, its own 10-year history, and analyst forward estimates.

Valuation context: This company is currently unprofitable with negative EBITDA. P/E and EV/EBITDA aren't meaningful; focus on EV/FCF and FCF Yield in the primary grid, plus revenue multiples (P/S, EV/Sales) in the expanded section.

What sector peers imply

Value if it traded at the sector-median multiple

What its own history implies

Value if it traded at its own 10-year median multiple

How the Multiples lens works

Five primary multiples surface the headline call; five additional multiples sit one click deeper for context.

Valuation multiples compare a company's market price to its financial fundamentals. The primary grid covers both the equity perspective (P/E, PEG, FCF Yield) and the enterprise value perspective (EV/EBITDA, EV/FCF) so you see how the market prices the company two ways simultaneously.

Price-based multiples use market cap and reflect what equity investors pay. EV-based multiples include debt and are better for comparing companies with different capital structures. The expanded section below adds P/B, P/S, P/FCF, EV/EBIT, and EV/Sales for additional perspective.

Learn more about the 5D valuation methodology

Immunic, Inc.· IMUX

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer

Search stocks

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer